Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 8, Issue 8, Pages 1057-1067Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.10.98
Keywords
cardiovascular; diabetes; glucose control; pioglitazone; PPAR-gamma
Categories
Funding
- AstraZeneca
- Merck Sharp Dohme
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi-Aventis
- Takeda
- Takeda Spain
Ask authors/readers for more resources
Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles. This action is mediated by its link to a nuclear receptor called peroxisome proliferator-activated receptor-gamma. By improving insulin sensitivity, hepatic glucose production decreases and glucose uptake increases in the peripheral tissues. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. In this article, current evidence concerning pioglitazone in the treatment of Type 2 diabetes will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available